THU dose. PO bioavailability of THU was less than 5 %, but did result in plasma concentrations associated with inhibition of its target CD. Human pilot studies showed comparable bioavailability for FdCyd (10 %) and THU (4.1 %). Conclusion Administration of THU with FdCyd increased the exposure to FdCyd and improved PO FdCyd bioavailability from <1 to 24 %. Concentrations of THU and FdCyd achieved after PO administration are associated with CD inhibition and hypomethylation, respectively. The schedule currently studied in phase I studies of PO FdCyd and THU is daily times three at the beginning of the first and second weeks of a 28-day cycle.
Introduction
5-Fluoro-2′-deoxycytidine (FdCyd, NSC48006) was originally developed as a cytidine deaminase (CDA)-activated prodrug for thymidylate synthase inhibitor 5-fluorouracil. However, by the mid-1980s, the combination of FdCyd and THU was proposed as an antineoplastic treatment for tumors resistant to 5FU [1] [2] [3] , suggesting a mechanism of action different from thymidylate synthase inhibition via 5-FU generation. Indeed, it was demonstrated that the administration of FdCyd with 3,4,5,6-tetrahydrouridine (THU, NSC112907) increased the incorporation of FdCyd into DNA and resulted in higher cytotoxicity [4] . Subsequently, FdCyd was shown to have activity as a DNA methyltransferase inhibitor through incorporation into DNA and formation of tight-binding complexes with DNA methyltransferase [5, 6] . In this respect, the ratio of FdCyd to FdUrd is an important pharmacological metric because FdCyd incorporation into DNA requires DNA synthesis and cell division, while its CDA-generated metabolite FdUrd is a cytotoxic which inhibits DNA replication [7] . The DNA-hypomethylating effects of FdCyd in combination with THU have been examined in vitro [8] where the combination of FdCyd and THU was compared with decitabine. Clinically, changes in DNA methyltransferase I and LINE1 methylation as well as upregulation of p16 expression were observed in paracentesis specimens from patients enrolled on an NCIsupported phase I clinical trial of IV FdCyd and THU [8] . The advantage of FdCyd over the FDA-approved agents decitabine and azacitidine is the aqueous stability of FdCyd, facilitating both intravenous (IV) dosing and the pursuit of an oral (PO)-dosing regimen [9, 10] .
FdCyd and THU have been evaluated in phase II clinical studies that use an IV route of administration. However, PO administration of this combination may allow for more prolonged exposure to FdCyd, which is desirable in hypomethylating therapy [4, 11] . In addition, it may be more convenient, requiring fewer office visits, which would reduce traveling to and waiting in the clinic. The preclinical studies reported here describe the PO and IV plasma pharmacokinetics of FdCyd, its metabolites, and THU and were designed to provide guidance for first-in-human studies of PO FdCyd and THU. 
Materials and methods

Chemicals and reagents
5-
Animals
Young, sexually mature male and female cynomolgus monkeys were individually housed in stainless steel cages and handled in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) and on a protocol approved by the Institutional Animal Care and Use Committee of IIT Research Institute (Chicago, IL). Each animal was uniquely identified by tattoo using number and/or letter combination. All animals were quarantined for a minimum of 42 days prior to the start of the study and received a detailed physical examination by a laboratory veterinarian prior to the initiation of dosing. In addition, all animals had a minimum of two consecutive negative TB tests. Body weights taken one week prior to treatment ranged from 2.5 to 4.0 kg. Room temperature was regulated at 22 ± 1 °C with relative humidity of 50 ± 30 %, and the rooms were kept on 12-h light/dark cycles. Animals were provided with certified, commercial monkey chow twice daily. Diets were supplemented with fresh fruit and/or other primate diet supplements. Water from the public supply was given ad libitum.
Treatments
For PO administration, animals (n = 4, 2 per sex/group) were dosed at 0.1, 1, or 10 mg/kg FdCyd by gavage, 1 h following administration of 500 mg/kg THU by gavage (Table 1) . Animals were dosed for four cycles, each consisting of dosing for three consecutive days followed by a 4-day dosing holiday. Dose levels of FdCyd and THU and the dose schedule used in this study were selected on the basis of the results of a previous study, in which severe gastrointestinal toxicity was observed in monkeys receiving daily exposure for 7 days to FdCyd at doses higher than 10 mg/kg/day in combination with THU at 150 mg/kg/day PO. Control monkeys (n = 8) received two oral gavage doses of water for injection (WFI), spaced 2 h apart. A dosing volume of 5 mL/ kg of body weight was used for both THU and FdCyd.
To characterize the pharmacokinetics of FdCyd alone, 10 mg/kg FdCyd was administered by gavage. The FdCyd and THU pharmacokinetics of PO FdCyd 1 h after THU was assessed on day 1 in all animals. To assess the bioavailability of FdCyd, animals (n = 2 per group) were dosed with 30 mg/kg THU and 4, 8, or 16 mg/kg FdCyd IV. An initial 20 % of the daily dose of THU was administered as an IV bolus injection immediately prior to the initiation of the FdCyd dose. The remaining 80 % of the THU dose was co-administered with the FdCyd dose as a 3-h infusion. The animals receiving 0.1 mg/kg FdCyd PO were re-used after a 4-day washout for the dosing of 0.1 mg/kg FdCyd with 500 mg/kg THU PO, which was justified based on the lack of clinical effects and the absence of detectable FdCyd concentrations after the first dosing. For clinical pathology determinations, blood was drawn on study days −6, 4, 8, 16, 19, 24, 29, and 43 and hematologic and clinical chemistry parameters were evaluated.
Sample collection
For pharmacokinetic analysis, heparinized blood samples (3 mL) were collected into tubes preloaded with 30 µL of 100 mg/mL zebularine before, and 15, 30, 60, 120, 240, 360, 480, and 1440 min after PO FdCyd dosing. For the IV group, heparinized blood samples (1 mL) were collected into tubes preloaded with 10 µL of 100 mg/mL zebularine before, and 15, 30, 60, 120, and 150 min after start, and at 15, 30, 60, 120, 240, 360, and 1440 min after end of infusion. Blood samples were centrifuged at 600×g for 10 min at 4 °C, and the resulting plasma was stored at −80 °C until analysis.
Human pilot study
In the first-in-human clinical trial of FdCyd, patients were administered a 3-h infusion of FdCyd concurrent with a fixed dose of THU. At FdCyd doses ≥20 mg/m 2 /d, peak plasma levels were above those that inhibit DNA methylation in vitro [12] . This trial included an expansion cohort where one of 10 IV dosing occasions was used to study the pharmacokinetics of PO-dosed FdCyd 100 mg/m 2 (equal to the IV dose) and THU at 1750 mg/ m 2 (fivefold the IV dose) [11] . The fivefold higher dose of THU by the PO route was based on earlier preclinical work suggesting approximately 20 % bioavailability of THU [13] . Pharmacokinetic samples were obtained both after IV and PO dosing for each patient. Plasma samples were obtained before and 15, 30, 60, 120, 150, 195, 210 min, and 4, 5, 7, 9, and 24 h after the start of the 3-h IV dosing, and before and 15, 30, 60 min, and 2, 4, 6, 9, and 24 h after PO dosing. Stabilization with zebularine and processing was as described above for animal blood draws.
This trial was conducted under a City of Hope-sponsored IND with institutional review board approval at each of the participating sites. The protocol design and conduct followed all applicable regulations, guidance, and local policies and were registered on ClinicalTrials.gov: NCT00378807.
Analytical methods
Plasma samples were analyzed for FdCyd, its metabolites FdUrd, FUrd, FU, FC, and THU by LC-MS/MS. For monkey plasma samples, plasma from untreated cynomolgus monkeys obtained from IIT Research Institute was used for standard curves for both the FdCyd and THU LC-MS/MS assays. Cynomolgus monkey plasma for the quality controls, run in triplicate with each assay, was purchased from Lampire Biological Laboratories (Pipersville, PA). For human samples, human control plasma was obtained from the Central Blood Bank, Pittsburgh, PA. The previously described FdCyd method [7, 12] was modified slightly in that [ 15 N 2 ]-5-FU was used as internal standard for FU, FdUrd, and FUrd, while 5′-deoxy-5-fluorocytidine served as internal standard for FdCyd and FC. A 10-µL mix of 10 µg/mL internal standards was added to each 100 µL plasma sample. THU plasma concentrations were quantitated with a previously developed and validated assay [14] .
Statistical analysis
Data were analyzed non-compartmentally using PK Solutions (Montrose, CO). Pharmacokinetic parameters were compared between groups with Minitab (State College, PA) via Kruskal-Wallis tests for overall significance, and pairwise comparisons were by Mann-Whitney. PK parameters across different doses were compared after dose normalization. Significance was set at p ≤ 0.05.
Results
Pharmacokinetics
In cynomolgus monkey plasma, the assays for FdCyd, FdUrd, FU, FC, and THU were linear, accurate, and precise over the same concentration ranges used for human and mouse plasma [7, 12] . FUrd could not be quantitated accurately, yet was detectable down to approximately 30 ng/mL; however, no FUrd peaks were detected in any of the samples. Table 2 ). In the 16-mg/kg FdCyd animals, a sudden increase in plasma concentrations of FdCyd and metabolites was observed at 150 min into the infusion, likely the result of an end-of-infusion push (data not shown), which was omitted for determining C max . FdCyd AUC 0-inf and C max appeared to increase a little more than proportional with dose, but these trends were not statistically significant (p > 0.18). No FC was detected in the plasma of any of the monkeys after IV dosing. The FdUrd concentrations were approximately 10-to 50-fold lower than FdCyd concentrations (Fig. 2a vs. b) .
FdCyd 10 mg/kg with 150 or 500 mg/kg THU PO versus FdCyd 8 mg/kg with 30 mg/kg THU IV in monkeys
Typical plasma concentration versus time profiles of individual monkeys following PO or IV administration of FdCyd and THU is shown in Fig. 1 . Plasma concentrations of FdCyd or downstream metabolites were not detectable in the plasma of monkeys receiving 10 mg/kg PO FdCyd without THU. Plasma FdCyd concentrations appeared to be slightly higher in monkeys that received FdCyd at 10 mg/ kg after 500 mg/kg versus 150 mg/kg THU; however, these plasma FdCyd concentrations were lower than those found in monkeys receiving 8 mg/kg FdCyd IV simultaneously with 30 mg/kg THU IV (Fig. 1c) . The estimated FdCyd PO bioavailability was 8.9 % with 150 mg/kg THU, while an increase in the THU dose to 500 mg/kg increased the FdCyd bioavailability to 25 % ( Table 2 ).
FdCyd 0.1, 1, or 10 mg/kg with 500 mg/kg THU PO in monkeys
Animals that received 0.1 mg/kg FdCyd PO as a single agent did not have detectable concentrations of FdCyd in their plasma, nor were any downstream metabolites of FdCyd detected (Fig. 2a, b 
mg/kg THU IV, 150 or 500 mg/kg THU PO with varying doses of FdCyd in monkeys
Within the 500-mg/kg THU dosing group, THU pharmacokinetic parameters appeared independent of FdCyd dose. High THU concentrations were observed at the end of the infusion for the 16-mg/kg FdCyd monkeys, and these data were excluded from the calculation of C max (see before). The half-life of THU ranged from 203 to 248 min, and concentrations of THU remained above 1000 ng/ml until 6 h after the end of infusion. Individual pharmacokinetic parameters are presented in Fig. 2 . Mean parameter values are provided in Table 2 , with bioavailability estimates of up to 4.4 %. (±1368) ng/mL, while PO administration of the same dose of FdCyd with a fivefold dose of THU resulted in a mean C max of FdCyd of 623 (±444) ng/mL (Table 3) . After IV dosing, the FdCyd to FdUrd ratio for C max (average and SD of individual ratios 187 ± 75) and AUC (134 ± 54) was higher than after PO dosing, with FdCyd to FdUrd ratio for C max (24 ± 19) and AUC (24 ± 11). FC was detected after PO dosing in 4 out of the 7 patients with an overall maximum concentration observed of 36.9 ng/mL. FdCyd PO bioavailability was estimated at approximately 10 %. THU PO bioavailability was estimated to be approximately 4.1 %. 
Preclinical study observations
Treatment of male and female monkeys with THU (500 mg/ kg) and FdCyd (0.1, 1.0, or 10.0 mg/kg) QDx3 every week, for 3 or 4 repeat 1-week cycles, did not result in any mortality or any signs of dose-limiting toxicity. The only test article-related clinical observation was diarrhea (primarily slight to moderate in severity) without any weight loss. This was observed in all monkeys receiving the drug combination at all three dose levels. Hematologic changes were limited to decreased leukocyte count and increased reticulocyte count in one female monkey in the high dose group; these changes were reversible within 7 days after the completion of dosing. 
Discussion
The toxicokinetic studies of FdCyd and THU in monkeys reported here were conducted to guide the NCI-sponsored phase I study of PO FdCyd and THU that is currently being conducted (ClinicalTrials.gov Identifier: NCT01534598).
Our data show the tolerability of a QDx3 weekly schedule, which was the starting schedule in an ongoing phase I trial of PO FdCyd and THU in patients with solid tumors (ClinicalTrials.gov Identifier: NCT01534598). To date, the gastrointestinal toxicity observed in this report has not been observed in the ongoing clinical trial, suggesting that the NHP species used were uniquely sensitive. PO FdCyd without THU resulted in undetectable FdCyd plasma concentrations, confirming the large first-pass effect of FdCyd and the need for THU co-administration. After PO dosing of FdCyd with 150 or 500 mg/kg THU, FdCyd apparent bioavailability reached 8.9 and 25 %, respectively, compared to IV FdCyd with 30 mg/kg THU. These values may be an underestimate of the potential bioavailability of FdCyd as the THU plasma exposure of 150 and 500 mg/ kg PO THU was still 4-and 2-fold less, respectively, than the THU plasma exposure after the 30 mg/kg IV THU dose. Furthermore, a 25 % PO bioavailability is a reasonable value for a pyrimidine drug and supports the PO route currently pursued in clinical trials as feasible. The 10-fold dose increases from 0.1 to 1, and 10 mg/kg PO FdCyd with 500 mg/kg THU resulted in increasing T max and a less than proportional increase in FdCyd exposure, suggesting saturable and more prolonged FdCyd absorption with increasing dose.
THU displayed an oral bioavailability of up to 4.2 %, which decreased with increasing dose. Despite the less than proportional 2.1-fold increase in THU plasma exposure, the dose increase of 150-500 mg/kg THU did result in effective threefold boosting of the FdCyd bioavailability from 8.9 to 25 %. Plasma THU exposure may be a determinant for FdCyd clearance, but perhaps less so for the FdCyd first-pass effect, which is likely determined by gastrointestinal and hepatic THU concentrations. Based on Freireich et al. [15] 2 THU-dosed IV [11] . The human pilot data after this IV dose and the PO data after 100 mg/m 2 FdCyd and 1750 mg/m 2 THU allowed calculation of human bioavailability, and IV and PO exposures (C max and AUC) and oral bioavailability showed remarkable agreement between monkeys and humans for both FdCyd and THU.
IV coadministration of FdCyd and THU resulted in favorable plasma exposure ratios of FdCyd to FdUrd, comparable to those observed in clinical studies of this combination [12] . Also after PO coadministration of FdCyd and THU, the FdCyd to FdUrd ratio was approximately 10-fold, suggesting that a pharmacologically desirable ratio is achievable with PO therapy.
We observed 5-FC plasma concentrations after 500, but not after 150 mg/kg THU co-administration with FdCyd, suggesting that only with an abundance of THU to block CD-mediated FdCyd degradation does bacterial pyrimidine nucleoside phosphorylase (EC 2.4.2.2) generate FC in quantities that are detectable in plasma, as observed in murine [7] and the human studies reported here. In man, pyrimidine nucleoside phosphorylase can metabolize most pyrimidine nucleosides except for 4-amino-substituted species like deoxycytidine [16] .
The chemical stability of FdCyd confers a significant advantage over both 5-aza-cytidine and decitabine, which are unstable [17] . In addition, our data show the feasibility of achieving meaningful FdCyd concentrations in both monkeys and humans after PO dosing of FdCyd and THU and the positive effect of higher THU doses on FdCyd bioavailability. Based on our results, a phase I trial of PO FdCyd and THU was initiated in patients with solid tumors (ClinicalTrials.gov Identifier: NCT01534598) and is currently ongoing. 
